MIC 401 Module 5

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/190

encourage image

There's no tags or description

Looks like no tags are added yet.

191 Terms

1
New cards

Virus Host Cell

can be animal, plant, fungal, bacteriophage

2
New cards

Virus Structure

geometrical shape of capsid (helical or icosahedron); absence or presence of an envelope (phospholipid bilayer from host cell)

3
New cards

Virus Nucleic Acid Types

DNA, RNA, reverse transcribing

4
New cards

DNA Viruses

double stranded and less common single stranded

5
New cards

RNA Viruses

positive sense single stranded, negative sense single stranded, and less common double stranded

6
New cards

Reverse Transcribing Viruses

double stranded DNA, single stranded RNA

7
New cards

Viral Genome

small in size; biggest is the mimvirus (~100 Kb) and smallest is the circovirus

8
New cards

Viral Nucleic Acid

genetic material of all viruses; single or double stranded DNA or RNA; linear or circular

9
New cards

Virus Protein Coat (Capsid)

protein shell that protects the nucleic acid; composed of repeating viral proteins (capsomeres) encoded by the viral genome

10
New cards

Virus Envelope

present in some viruses; host derived phospholipid bilayer with viral glycoproteins

11
New cards

Virion

viral particle; consists of envelope glycoproteins, envelope, capsid, and viral nucleic acid

12
New cards

Advantages of Virion Structure

protection of the fragile nucleic acid genome from physical, chemical, or enzymatic damage; specificity/recognition and first interaction with host cell; delivery of genome into the cell

13
New cards

Viruses - A Problem

nucleotides have approximately 3x the mass of amino acid residues; viral capsids have limited space for packaging the genome

14
New cards

Virus Subunits

construction is based upon hydrophobic and electrostatic interactions; all viruses important in human disease have capsids

15
New cards

General Virus Replication Cycle

attachment and entry → uncoating and genome release → genome replication and protein synthesis → envelope glycoprotein synthesis and processing (ER) → assembly of nucleocapsid with genome → budding and maturation (ER/Golgi/PM) → mature virion release

16
New cards

Antibodies

a large protein produced by the immune system to identify and neutralize foreign objects (antigens); IgG and IgM

17
New cards

IgG

majority of the antibody response to pathogens

18
New cards

IgM

early stages of antibody-based immune reaction

19
New cards

Immunogenicity

ability of a substance to induce an adaptive immune response

20
New cards

Complete Antigens

proteins, polysaccharides, and lipids

21
New cards

Haptens

incomplete antigens; small molecules (various drugs like penicillin)

22
New cards

Passive Immunization

preformed antibodies from an external source; immediate protection, no memory; maternal IgG from placenta, maternal IgA from breastmilk, therapeutic antiserum/monoclonal antibodies

23
New cards

Active Immunization

exposure to antigen (infection or vaccine); induced the body to produce antibodies and cell-mediated responses; generates long lasting immunity (B and T Cells)

24
New cards

How Do We Measure Virus Neutralization?

viruses that are cytotoxic can be quantified by plaque-forming essays

25
New cards

Plaque Forming Units (PFU)

a measure of the number of infectious virus particles; determined by an assay in which infectious virus produces zones of infected-cell lysis in a cell monolayer

26
New cards

Multiplicity of Infection (MOI)

the average number of virus particles/infectious units infecting each cell; equals the PFU of virus used for infection/number of cells

27
New cards

IC50

half maximal inhibitory concentration; measure of the potency of a substance in inhibiting a specific biological or biochemical function; indicates how much of an inhibitory substance is needed to stop a biological process by 50%

28
New cards

PRNT50 Assay

gives us a way to compare the effectiveness of inhibitors; example → a patient’s antibodies

29
New cards

Hepatitis Viruses

vowels are acute, consonants are chronic; AB have vaccines

30
New cards

Hepatitis

inflammation of the liver; can lead to encephalopathy, eye jaundice, muscle aches and weakness, inflammation and bleeding of the esophagus, jaundice of the skin, spleen enlargement, stomach/pancreas inflammation

31
New cards

Hepatits A Virus (HAV)

fecal oral transmission, widespread subclinical infections; incubation period is 15-45 days; acute infection only; non-enveloped; icosahedral capsid (VP1-4); + ssRNA (picornavirus)

32
New cards

HAV - Immune Response

IgM antibodies are detectable first (acute infection); IgG antibodies are detectable for life (lasting immunity)

33
New cards

HAV - Diagnosis

serology - raised IgM and IgG (6 weeks after symptom onset); elevated liver enzymes, especially ALT

34
New cards

HAV - Virus Oddity

requires an intact eukaryote initiating factor 4g for initiation of translation; cannot shut fown host cell translation; must compete with the cell for elF4G; no cytotoxicity

35
New cards

Hepatitis Viruses - Membrane Hijacking

new evidence that HAV and HEV (and polio) exist outside the cell in two equally infectious forms; one enveloped, one not; they circulate in the blood in a membrane bound form and are shed in the feces without an envelope

36
New cards

HAV - Treatment

no specific method; rest, avoid alcohol and any toxic substances; over 85% of people recover within 3 months, nearly all patients recover within 6 months

37
New cards

HAV - Prevention

passive immunization from human gamma globulin; active immunization from vaccine (age > 1 year) and combined vaccine with HBV (age 18 years and over)

38
New cards

Hepatits B Virus (HBV)

major cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma; incubation period is 45-160 days

39
New cards

HBV - Transmission

bloodborne, infectious blood or body fluids (semen, vaginal fluids); perinatal infection; also via close contact (sharing utensils, kissing, higging, breastfeeding)

40
New cards

HBV - Clinical Symptoms

appetite loss, fatigue, fever (low grade), muscle or joint aches, nausea and vomiting, jaundice (yellow skin) and dark urine

41
New cards

HBV - Immune Response

IgG (anti-HBs) antibodies usually persist for life after infection or immunization

42
New cards

HBV - Diagnosis

liver function tests (ALT elevation); serology (HBsAg, anti-HBc, anti-HBs) and/or viral DNA

43
New cards

HBV - Virion Structure

partially double stranded DNA genome; HBcAg capsid; polymerase (reverse transcriptase); HBsAg surface proteins; secretes HBeAg; HBx regulatory proteins

44
New cards

HBV - HBsAg Surface Proteins

all three share the S region - major antigenic determinant

45
New cards

HBV - Particle Types in the Blood

dane particle (infectious virion); spherical subviral particle (HBsAg only); filamentous subviral particle (HBsAg only)

46
New cards

HBV - Viral Hepatitis B

infects about a third of the worlds population some time in their lives; replicate through an RNA intermediate by activity of reverse transcriptase which relates them to retroviruses like HIV; partially dsDNA molecule genome and has a virion-associated DNA polymerase; 350 million are chronic carriers

47
New cards

HBV - Asymptomatic/Subclinical Infection

majority of infectious; HBsAg in serum for a short time (1-2 months); antibodies against HBsAg persist for life providing lifelong immunity

48
New cards

HBV - Acute Infection

long incubation period (43-180 days); symptoms as in acute hepatitis A; HBsAg in serum for 6 months (transient); majority of patients recover; antibodies against HBsAg persist for lifetime providing lifelong immunity

49
New cards

Fulminant Hepatitis

HBV + HDV; sudden and quick, intense and severe to point of lethality

50
New cards

HBV - Chronic Infection

one of the common long term results of acute infection is called persistent viral hepatitis; HBsAg in serum persists for over 6 months, probably for life

51
New cards

HBV - Treatment

interferon alpha (decreases stability of viral genome, causes side effects); nucleoside/nucleotide analogs whihc inhibit reverse transcriptase (initially HIV treatment); still work to determine optimal strategies

52
New cards

HBV Prevention - Recombivax

recombinant HBV surface antigen; traditional hep B vaccine

53
New cards

HBV Prevention - Engerix

recombinant HBsAg; similar antigen, different formulation

54
New cards

HBV Prevention - Twinrix

inactivated HAV and recombinant HBV HBsAg; combined HAV and HBV vaccine

55
New cards

HBV Prevention - Hepilsav

recombinant HBsAg + adjuvant; two dose adult series, generally one month apart

56
New cards

HCV - Transmission

IV drug use, blood transfusion (in countries without screening), tattooing with non-sterile equipment, sharing razors, manicure/pedicure equipment (parenteral)

57
New cards

HCV - Clinical Symptoms

right upper quadrant abdominal pain; ascites/abdominal swelling; clay colored or pale stools; dark urine, fatigue, fever, itching, jaundice; loss of appetite, nausea, vomiting

58
New cards

HCV - Immune Response

IgG antibodies usually persist for life after infection

59
New cards

HCV - Diagnosis

blood tests (antibodies); liver function tests; genetic testing (six genotypes, 1 is common in U.S., 2 and 3 are easier to treat); liver biopsy to determine extent of damage

60
New cards

HCV - Virion and Genome

enveloped, + ssRNA produces a single polyprotein; mutates rapidly due to high error rate of RNA-dependent RNA polymerase; E1 and E2 envelope glycoproteins (mediate receptor binding and entry)

61
New cards

HCV - Clinical Picture

15-150 day incubation period; most infections are insidious (slow); 10 years to clinical hepatitis, 21 years to liver cirrhosis, 29 years to develop hepatocellular carcinoma

62
New cards

HCV - Treatment

combination of pegylated interferon alpha and the antiviral drug ribavirin for 24-48 weeks depending upon the genotype; ribavarin; more effective during the first six months as opposed to after infection has become chronic

63
New cards

HCV - Prevention

no vaccine

64
New cards

HCV - PEG

polyethylene glycol used by pharmaceutical companies; stabilizing agent, slowed clearance from the blood, enhanced permeability and retention in tumors

65
New cards

HCV - New Drugs

direct acting antivirals; remove all traces of the virus from the blood in 12 weeks; sustained viriologic response; treatment varies from 8-24 weeks; now called the IFN free era

66
New cards

HCV - NS3/4A Viral Protein

viral protease (polyprotein processing); target for protease inhibitors (glecaprevir, grazoprevir, voxilaprevir)

67
New cards

HCV - NS5A Viral Protein

organizes viral RNA replication complexes and helps assemble new virions; target for inhibitors (velpatasvir, pibrentasvir, ledipasvir)

68
New cards

HCV - NS5B Viral Protein

RNA dependent RNA polymerase that synthesizes viral RNA; target for polymerase inhibitors (sofosbuvir)

69
New cards

Hepatits D Virus (HDV)

transmission is bloodborne, sexual, needle sharing, infected blood products; incubation period is 30-60 days

70
New cards

HDV - Clinical Symptoms

more severe than other hepatitis viruses; abdominal pain and swelling, loss of appetite, sore throat, joint and muscle pain, clay-colored or pale stools, dark urine, fatigue, fever, itching, jaundice, nausea, vomiting

71
New cards

HDV - Immune Response

anti-HD antibodies do not always persist after acute infection is cleared

72
New cards

HDV - Diagnosis

anti-delta/HD antibodies; serum RNA

73
New cards

HDV - Virion

defective RNA virus that requires hepatitis B surface proteins (HBsAg) for assembly and release, infection occurs only in people with current HBV infection; uses HBsAg to assemble its envelope and exit infected hepatocytes; replicates (-) ssRNA using host enzymes, independent of HBV polymerase; has a delta antigen

74
New cards

HDV - Large HBsAg

enables HDV attachment to the hepatocyte receptor NTCP and entry into cells

75
New cards

HDV - HBV Vaccination

also prevents infection by preventing the HBV infection needed to supply HBsAg

76
New cards

HDV - Treatment

no effective antivirals; progression to cirrhosis usually takes 5-10 years, but it can appear 2 years after infection onset; about 60-70% of patients develop cirrhosis and die from hepatic failure; liver transplant may be considered for fulminant acute or end stage chronic disease; mortality is 10x higher than HBV alone

77
New cards

HEV - Transmission

fecal oral route; primarily via contaminated water due to poor sanitation; incubation period of 15-60 days

78
New cards

HEV - Clinical Symptoms

jaundice, dark urine, pale stools, anorexia, enlarged/tender liver, abdominal pain and tenderness, nausea and vomiting, fever

79
New cards

HEV - Immune Response

noncytopathic (does not directly kill cells), but suspected to cause immune-mediated liver damage through cytotoxic T cells

80
New cards

HEV - Diagnosis

detection of specific anti-HEV antibodies in blood; often associated with outbreaks (ex, waterborne)

81
New cards

HEV - Virion

non enveloped; ORF2 capsid protein; + ssRNA

82
New cards

HEV - Treatment

none available; usually self limiting; hospitalization required for patients with fulminant disease

83
New cards

HEV - Prevention

maintain quality standards for public water supplies; proper disposal and treatment of waste; vaccine available in china, but not in the U.S.

84
New cards

Orthomyxoviruses

negative sense ssRNA; mRNA is in the positive sense *must be converted to positive sense mRNA before translation); segmented genome allows for gene re-assortment; alpha, neta, gamma, delta genera

85
New cards

Influenza

respiratory infection; incubation period is 1-4 days, lasts 1-2 weeks; complications include pneumonia, bronchitis, sinusitis, croup, COPD, exacerbation, reye’s syndrome, inflammation of the heart, muscles, or pericardium

86
New cards

High Fever and Muscle/Joint Pain

what sets the flu apart from common cold

87
New cards

Influenza Transmission

mostly through the air by respiratory park caused by coughs and sneezes (not long lasting in the air); from infected birds through their droppings; also by saliva, nasal secretions, feces, and blood

88
New cards

Influenza Virion

relatively labile (easy to degrade) because of the phospholipid bilayer; needs to stay hydrated to survive; easily destroyed by detergent; survive several hours in mucus

89
New cards

Structure of the Influenza Virion and Its Genome Segments

has HA/NA; 8 RNA genome segments, each encoding one or more viral proteins → enables genetic reassortment; vRnP complex of each gene that consists of RNA polymerases and NP-coated viral RNA

90
New cards

Influenza RNP Packaging - Segment Packaging Signals

located near the 3’ and 5’ ends of each viral RNA segment and extend into adjacent coding regions; help distinguish one segment from another

91
New cards

Influenza RNP Packaging - Segment Recognition

specific RNA interactions help bring different viral ribonucleoprotein complexes together into a coordinated set

92
New cards

Influenza RNP Packaging - Segment Assembly

forms a 7+1 pattern; electron microscopy shows seven vRNPs surrounding one central vRNP

93
New cards

Influenza RNP Packaging - Assembled Genome

incorporated into a budding virion; viral proteins, including M1 and the membrane associated machinery help coordinate genome incorporation during budding

94
New cards

Influenza Replication Cycle

adhesion → endocytosis → pH triggers conformational change → fusion and uncoating → replication and protein synthesis → assembly → budding → release

95
New cards

Influenza Antigenic Drift

error-prone RNA dependent RNA polymerase; point mutations in multiple antigenic sites of HA; eventually virus is no longer effectively neutralized by antibodies to parent virus; vaccine will no longer prevent disease; humans mat still have some protection lessening severity → seasonal flu requires new vaccine each year

96
New cards

Influenza Antigenic Shift

segmented genome allows for reassortment of HA and NA genes; occurs in cells infected with different human and animal viruses; resulting virus has novel antigenic properties; humans have no protection; disease can be severe → causes human epidemics/pandemics

97
New cards

Influenza Hemagglutinin (HA)

binds to sialic acid receptors; mediates membrane fusion into the endosome; binds to proteoglycans on the cell surface that terminate in sialic acid

98
New cards

Influenza Neuraminidase (NA)

glycoside hydrolase that cleaves sialic acid; releases particles after maturation; breaks down mucins in respiratory tract

99
New cards

a2,3-sialyated Glycans

avian like, deeper in the lungs; when bound by influenza, produces a slower spread but more fatal disease

100
New cards

a2,6-sialyated Glycans

human like, more shallow in the lungs; when bound by influenza, produces a faster spreading but milder disease